Comment on

• Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.

  Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J. Xu J, et al. J Clin Oncol. 2018 Feb 1;36(4):350-358. doi: 10.1200/JCO.2017.74.3245. Epub 2017 Dec 7. J Clin Oncol. 2018. PMID: 29215955 Clinical Trial.
• Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.

  Sun R, Horiguchi M, Wei LJ. Sun R, et al. J Clin Oncol. 2018 May 1;36(13):1378-1379. doi: 10.1200/JCO.2017.77.5643. Epub 2018 Mar 20. J Clin Oncol. 2018. PMID: 29558278 No abstract available.
• Statistical and Clinical Significance in the TERRA Study.

  Di Nardo P, Addeo A. Di Nardo P, et al. J Clin Oncol. 2018 May 1;36(13):1379-1380. doi: 10.1200/JCO.2018.77.9595. Epub 2018 Mar 20. J Clin Oncol. 2018. PMID: 29558280 No abstract available.